Pharmaceutical composition for treating metabolism-related fatty liver disease as well as preparation method and application thereof

A composition and drug technology, applied in the field of medicine, can solve the problems of inability to improve liver histological changes and side effects, and achieve the effects of clear dosage, convenient administration, and small molecular weight

Inactive Publication Date: 2021-05-28
北京泛亚同泽生物医学研究院有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] To this end, the present invention provides a pharmaceutical composition for treating metabolic-related fatty liver disease and its preparation method and application, so as to solve the problem that most of the existing drugs for treating metabolic-related fatty liver disease focus on improving related metabolic indicators but cannot improve liver function. Histological changes, side effects, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating metabolism-related fatty liver disease as well as preparation method and application thereof
  • Pharmaceutical composition for treating metabolism-related fatty liver disease as well as preparation method and application thereof
  • Pharmaceutical composition for treating metabolism-related fatty liver disease as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] A pharmaceutical composition for treating metabolic-related fatty liver disease is prepared from the following raw materials in parts by weight: 10 g of ginseng extract, 10 g of sorbitol, 10 g of microcrystalline cellulose, 10 g of magnesium stearate, and 10 g of transparent coating agent .

[0034] The dosage form of the finished preparation of the pharmaceutical composition is an acceptable dosage form prepared by conventional technical methods in pharmacy. The dosage form is preferably a tablet.

[0035] The preparation method of above-mentioned pharmaceutical composition comprises the steps:

[0036]Dissolve 50 g of red ginseng extract in an appropriate amount of deionized water to dissolve completely, then extract with chloroform for 3 times, combine the upper layer solutions to obtain a crude extract, and set aside. Put the crude extract into the pretreated macroporous resin chromatography column, after static adsorption for 20min, first elute with 2000mL of wat...

Embodiment 2

[0039] A pharmaceutical composition for treating metabolic-related fatty liver disease is prepared from the following raw materials in parts by weight: 10 g of ginseng extract, 100 g of sorbitol, 20 g of microcrystalline cellulose, 5 g of magnesium stearate, and 5 g of transparent coating agent .

[0040] The preparation method of the above-mentioned pharmaceutical composition is the same as in Example 1.

Embodiment 3

[0042] A pharmaceutical composition for treating metabolic-related fatty liver disease is prepared from the following raw materials in parts by weight: 10 g of ginseng extract, 100 g of sorbitol, 15 g of microcrystalline cellulose, 2 g of magnesium stearate, and 2 g of transparent coating agent .

[0043] The preparation method of the above-mentioned pharmaceutical composition is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating metabolism-related fatty liver diseases and a preparation method and application thereof, and relates to the technical field of medicines. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 1-100 parts of a ginseng extract, 1-1000 parts of sorbitol, 1-200 parts of micro-crystalline cellulose, 1-50 parts of magnesium stearate and 1-50 parts of a transparent coating agent. The pharmaceutical composition disclosed by the invention can improve lipid metabolism, reduce synthesis of triglyceride and cholesterol in the liver, reduce aggregation of triglyceride in the liver, improve histological change of the liver, improve the glucose metabolism, reduce the fasting blood glucose level, improve the glucose tolerance, promote the expression of decoupling protein 1, enhance the activity of brown fat, promote energy metabolism, and reduce the release of ALT and AST, can be used for treating metabolism-related fatty liver diseases, metabolism-related steatohepatitis and other diseases, and is obvious in curative effect, small in side effect and wide in adaptation disease range.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating metabolic-related fatty liver disease, a preparation method and application thereof. Background technique [0002] It is estimated that hundreds of millions of people around the world are affected by liver diseases. In China, more than one-fifth of the population suffers from liver diseases, especially hepatitis B, C, cirrhosis, liver cancer, and non-alcoholic fatty liver disease. Fatty liver disease (NAFLD), alcoholic liver disease (ALD) and drug-induced liver injury make liver disease one of the main factors affecting morbidity and mortality in China. In recent years, the incidence of viral hepatitis has been declining in most developed countries due to modern advances in disease prevention, diagnosis, and treatment. At the same time, with the promotion of immunization programs against hepatitis B virus in many countries, including Ch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/258A61K9/20A61K47/26A61K47/38A61K47/12A61P1/16A61P3/00
CPCA61K9/2013A61K9/2018A61K9/2054A61K36/258A61P1/16A61P3/00
Inventor 高杰芦红萍
Owner 北京泛亚同泽生物医学研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap